Literature DB >> 9200152

Intervention of transplantable human mammary carcinoma MX-1 chemotherapy with dietary menhaden oil in athymic mice: increased therapeutic effects and decreased toxicity of cyclophosphamide.

Y Shao1, L Pardini, R S Pardini.   

Abstract

We investigated the effects of dietary menhaden oil on cyclophosphamide (CP) antineoplastic activity and its protective effect against CP toxicity. We found that dietary menhaden oil (HMO, 20% menhaden oil + 5% corn oil) enhanced the CP antitumor effect at the lowest dose tested (50 mg/kg) compared with the control group (LCO, 5% corn oil). Dietary HMO and CP treatment had a significant effect on the activities of tumor and liver microsomal cytochrome P-450 (CYP) over the controls. Activity of one of the key CP activating enzymes, CYP2B1 (which is similar to human CYP2B6), was significantly enhanced in the liver and tumor by the HMO diet, which could result in the formation of more pharmacologically active CP metabolites and, therefore, increased CP antitumor response. Moreover, the HMO diet exhibited a very significant protective effect against CP acute toxicity. The activity of the CP detoxifying enzyme aldehyde dehydrogenase (ADH) was significantly increased in the liver after HMO feeding; thus the observed protective effect of HMO feeding against CP toxicity may be partially the result of induction of ADH activity in the liver. In summary, our findings suggested that dietary menhaden oil can modulate ADH and CYP activities in a manner that may alter the metabolism of CP and, therefore, improve its therapeutic index by increasing its therapeutic effect and decreasing its toxicity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9200152     DOI: 10.1080/01635589709514554

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  8 in total

1.  Effects of caloric intake on intestinal mucosal morphology and immune cells in rats treated with 5-Fluorouracil.

Authors:  Mariko Murakami; Norifumi Sato; Katsufumi Tashiro; Tsuyoshi Nakamura; Hiroaki Masunaga
Journal:  J Clin Biochem Nutr       Date:  2009-06-30       Impact factor: 3.114

2.  Cytotoxic drugs efficacy correlates with adipose tissue docosahexaenoic acid level in locally advanced breast carcinoma.

Authors:  P Bougnoux; E Germain; V Chajès; B Hubert; C Lhuillery; O Le Floch; G Body; G Calais
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

3.  Consumption of an omega-3 fatty acids product, INCELL AAFA, reduced side-effects of CPT-11 (irinotecan) in mice.

Authors:  W E Hardman; M P Moyer; I L Cameron
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

4.  N-3 polyunsaturated fatty acids decrease levels of doxorubicin-induced reactive oxygen species in cardiomyocytes -- involvement of uncoupling protein UCP2.

Authors:  Hsiu-Ching Hsu; Ching-Yi Chen; Ming-Fong Chen
Journal:  J Biomed Sci       Date:  2014-11-18       Impact factor: 8.410

Review 5.  Diet composition as a source of variation in experimental animal models of cancer cachexia.

Authors:  Kaitlin Giles; Chen Guan; Thomas R Jagoe; Vera Mazurak
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-10-15       Impact factor: 12.910

Review 6.  ω-3 Long Chain Polyunsaturated Fatty Acids as Sensitizing Agents and Multidrug Resistance Revertants in Cancer Therapy.

Authors:  Paola Antonia Corsetto; Irma Colombo; Joanna Kopecka; Angela Maria Rizzo; Chiara Riganti
Journal:  Int J Mol Sci       Date:  2017-12-20       Impact factor: 5.923

7.  Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial.

Authors:  P Bougnoux; N Hajjaji; M N Ferrasson; B Giraudeau; C Couet; O Le Floch
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

8.  Omega 3 fatty acids increase the chemo-sensitivity of B-CLL-derived cell lines EHEB and MEC-2 and of B-PLL-derived cell line JVM-2 to anti-cancer drugs doxorubicin, vincristine and fludarabine.

Authors:  Johannes F Fahrmann; W Elaine Hardman
Journal:  Lipids Health Dis       Date:  2013-03-16       Impact factor: 3.876

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.